Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Urinary Tract Infections-Pipeline Review, H1 2015

Urinary Tract Infections-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Urinary Tract Infections-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Urinary Tract Infections-Pipeline Review, H1 2015', provides an overview of the Urinary Tract Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Urinary Tract Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Urinary Tract Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Urinary Tract Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Urinary Tract Infections Overview 10

Therapeutics Development 11

Pipeline Products for Urinary Tract Infections-Overview 11

Pipeline Products for Urinary Tract Infections-Comparative Analysis 12

Urinary Tract Infections-Therapeutics under Development by Companies 13

Urinary Tract Infections-Therapeutics under Investigation by Universities/Institutes 16

Urinary Tract Infections-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Urinary Tract Infections-Products under Development by Companies 20

Urinary Tract Infections-Products under Investigation by Universities/Institutes 23

Urinary Tract Infections-Companies Involved in Therapeutics Development 24

Achaogen Inc. 24

Adenium Biotech ApS 25

AstraZeneca PLC 26

ConjuGon, Inc. 27

Cubist Pharmaceuticals, Inc. 28

Da Volterra 29

DexTech Medical AB 30

FOB Synthesis, Inc. 31

GlycoVaxyn AG 32

Melinta Therapeutics, Inc 33

Merck & Co., Inc. 34

MerLion Pharmaceuticals Pte Ltd 35

Nabriva Therapeutics AG 36

NovaBay Pharmaceuticals, Inc. 37

Nymox Pharmaceutical Corporation 38

Osel Inc. 39

Paratek Pharmaceuticals, Inc. 40

Sequoia Sciences, Inc. 41

Shionogi & Co., Ltd. 42

Syntiron LLC 43

Tetraphase Pharmaceuticals Inc. 44

The Medicines Company 45

Urinary Tract Infections-Therapeutics Assessment 46

Assessment by Monotherapy Products 46

Assessment by Combination Products 47

Assessment by Target 48

Assessment by Mechanism of Action 50

Assessment by Route of Administration 52

Assessment by Molecule Type 54

Drug Profiles 56

(ceftaroline fosamil + avibactam sodium)-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

(ceftazidime + avibactam sodium)-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

(ceftolozane sulfate + tazobactam sodium)-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

(meropenem+ RPX-7009)-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

AA-139-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

auriclosene-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

C-1205-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

CatDex-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

cefepime-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

DAV-210-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

delafloxacin-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

Drugs to Inhibit COX-2 for Urinary Tract Infections-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

EBX-002-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

eravacycline-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Escherichia coli vaccine-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

extraintestinal pathogenic escherichia coli vaccine-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

finafloxacin-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

FSI-1686-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

GP-4-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

klebsiella pneumoniae vaccine-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

LACTIN-V-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

Micselon-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

Nu-2-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Nu-3-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

NXB-4221-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

omadacycline-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

plazomicin sulfate-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

Proteins for Infectious Diseases-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

relebactam-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

S-649266-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

Small Molecules to Inhibit 23S Ribosomal RNA for Infections-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

Vaccine for Urinary Tract Infection-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

ZTI-01-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

Urinary Tract Infections-Recent Pipeline Updates 102

Urinary Tract Infections-Dormant Projects 125

Urinary Tract Infections-Discontinued Products 127

Urinary Tract Infections-Product Development Milestones 128

Featured News & Press Releases 128

Jan 08, 2015: MerLion's Finafloxacin Shows Positive Phase 2 Results in Complicated Urinary Tract Infections 128

Dec 19, 2014: FDA approves new antibacterial drug Zerbaxa 129

Dec 05, 2014: Anti-Infective Advisory Committee Recommends Approval Of Actavis' Ceftazidime-Avibactam 129

Oct 08, 2014: Tetraphase Pharmaceuticals Announces Presentation of Data at IDWEEK on the Activity of Eravacycline Against Multidrug-Resistant Bacteria 130

Oct 06, 2014: Tetraphase Pharmaceuticals Announces Initiation of Pivotal Portion of IGNITE 2 Phase 3 Trial of Eravacycline in cUTI 131

Sep 04, 2014: Merck's Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA 132

Sep 02, 2014: Tetraphase Pharmaceuticals Announces Positive Oral Dosing Data from Lead-in of IGNITE 2 Phase 3 Trial of Eravacycline in cUTI Support Advancement to Pivotal Portion 132

Jul 28, 2014: Tetraphase Pharmaceuticals Completes Enrollment of IGNITE 1 Eravacycline Phase 3 Clinical Trial in Complicated Intra-abdominal Infections 133

Jul 01, 2014: GlycoVaxyn announces the initiation of a Phase I clinical trial in collaboration with Janssen for a vaccine against Extra-intestinal pathogenic Escherichia coli causing urinary tract infection 134

Jun 19, 2014: Cubist Announces Acceptance of Ceftolozane/Tazobactam New Drug Application with Priority Review 135

Appendix 136

Methodology 136

Coverage 136

Secondary Research 136

Primary Research 136

Expert Panel Validation 136

Contact Us 136

Disclaimer 137

List of Tables

Number of Products under Development for Urinary Tract Infections, H1 2015 11

Number of Products under Development for Urinary Tract Infections-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 14

Number of Products under Development by Companies, H1 2015 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Late Stage Development, H1 2015 17

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Development, H1 2015 19

Products under Development by Companies, H1 2015 20

Products under Development by Companies, H1 2015 (Contd..1) 21

Products under Development by Companies, H1 2015 (Contd..2) 22

Products under Investigation by Universities/Institutes, H1 2015 23

Urinary Tract Infections-Pipeline by Achaogen Inc., H1 2015 24

Urinary Tract Infections-Pipeline by Adenium Biotech ApS, H1 2015 25

Urinary Tract Infections-Pipeline by AstraZeneca PLC, H1 2015 26

Urinary Tract Infections-Pipeline by ConjuGon, Inc., H1 2015 27

Urinary Tract Infections-Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 28

Urinary Tract Infections-Pipeline by Da Volterra, H1 2015 29

Urinary Tract Infections-Pipeline by DexTech Medical AB, H1 2015 30

Urinary Tract Infections-Pipeline by FOB Synthesis, Inc., H1 2015 31

Urinary Tract Infections-Pipeline by GlycoVaxyn AG, H1 2015 32

Urinary Tract Infections-Pipeline by Melinta Therapeutics, Inc, H1 2015 33

Urinary Tract Infections-Pipeline by Merck & Co., Inc., H1 2015 34

Urinary Tract Infections-Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2015 35

Urinary Tract Infections-Pipeline by Nabriva Therapeutics AG, H1 2015 36

Urinary Tract Infections-Pipeline by NovaBay Pharmaceuticals, Inc., H1 2015 37

Urinary Tract Infections-Pipeline by Nymox Pharmaceutical Corporation, H1 2015 38

Urinary Tract Infections-Pipeline by Osel Inc., H1 2015 39

Urinary Tract Infections-Pipeline by Paratek Pharmaceuticals, Inc., H1 2015 40

Urinary Tract Infections-Pipeline by Sequoia Sciences, Inc., H1 2015 41

Urinary Tract Infections-Pipeline by Shionogi & Co., Ltd., H1 2015 42

Urinary Tract Infections-Pipeline by Syntiron LLC, H1 2015 43

Urinary Tract Infections-Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 44

Urinary Tract Infections-Pipeline by The Medicines Company, H1 2015 45

Assessment by Monotherapy Products, H1 2015 46

Assessment by Combination Products, H1 2015 47

Number of Products by Stage and Target, H1 2015 49

Number of Products by Stage and Mechanism of Action, H1 2015 51

Number of Products by Stage and Route of Administration, H1 2015 53

Number of Products by Stage and Molecule Type, H1 2015 55

Urinary Tract Infections Therapeutics-Recent Pipeline Updates, H1 2015 102

Urinary Tract Infections-Dormant Projects, H1 2015 125

Urinary Tract Infections-Dormant Projects (Contd..1), H1 2015 126

Urinary Tract Infections-Discontinued Products, H1 2015 127

List of Figures

Number of Products under Development for Urinary Tract Infections, H1 2015 11

Number of Products under Development for Urinary Tract Infections-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 17

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Products, H1 2015 19

Assessment by Monotherapy Products, H1 2015 46

Assessment by Combination Products, H1 2015 47

Number of Products by Top 10 Targets, H1 2015 48

Number of Products by Stage and Top 10 Targets, H1 2015 48

Number of Products by Top 10 Mechanism of Actions, H1 2015 50

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 50

Number of Products by Top 10 Routes of Administration, H1 2015 52

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 52

Number of Products by Top 10 Molecule Types, H1 2015 54

Number of Products by Stage and Top 10 Molecule Types, H1 2015 54

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Achaogen Inc.

Adenium Biotech ApS

AstraZeneca PLC

ConjuGon, Inc.

Cubist Pharmaceuticals, Inc.

Da Volterra

DexTech Medical AB

FOB Synthesis, Inc.

GlycoVaxyn AG

Melinta Therapeutics, Inc

Merck & Co., Inc.

MerLion Pharmaceuticals Pte Ltd

Nabriva Therapeutics AG

NovaBay Pharmaceuticals, Inc.

Nymox Pharmaceutical Corporation

Osel Inc.

Paratek Pharmaceuticals, Inc.

Sequoia Sciences, Inc.

Shionogi & Co., Ltd.

Syntiron LLC

Tetraphase Pharmaceuticals Inc.

The Medicines Company

Urinary Tract Infections Therapeutic Products under Development, Key Players in Urinary Tract Infections Therapeutics, Urinary Tract Infections Pipeline Overview, Urinary Tract Infections Pipeline, Urinary Tract Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com